Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate.
Gilead’s hepatitis C treatment Sovaldi will top the list of biggest selling drugs in 2020, according to UK market intelligence company, Evaluate.
“Given its history-making launch, it is no surprise that [Sovaldi] is forecast to become the biggest drug in 2020; the big question will be how long this drug can hang onto the top spot,” said Lisa Urquhart, leader of Evaluate’s EP Vantage editorial team.
For Sovaldi to remain a $13bn+ franchise after 2017, several assumptions need to play out, says EP Vantage. The number of new patients seeking treatment for hepatitis C each year must hold up, particularly in the US, while Gilead also needs to maintain the product’s price. This could be driven down by payers or aggressive price competition from new entrants.
EP Vantage’s “Biggest Drugs 2020” also reveals a surprise entrant to the list of 2020′s top selling drugs in Bristol-Myers Squibb’s anti-PD-1 antibody, nivolumab. While this remains the list’s “biggest unknown”, as an immune checkpoint inhibitor it promises big improvements in the treatment of cancers like melanoma and lung, says the report. “With the first phase III data due to start emerging towards the end of this year or early 2015, the real potential of nivolumab and others in its class will soon be judged with greater insight.”
Evaluate’s annual report, “World Preview 2014: Outlook to 2020”, examining the impact of patent expirations and analysing R&D spend as well as the leading products and companies, will be launched at next month’s 2014 BIO Convention in San Diego, CA (June 23–26).
For more information on the “Biggest Drugs of 2020″, click here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
AbbVie’s Emraclidine Fails to Reduce Schizophrenia Symptoms Compared to Placebo
November 11th 2024Results from the Phase II EMPOWER trial found that emraclidine failed to meet its primary endpoint of reducing Positive and Negative Syndrome Scale scores after six weeks of treatment for schizophrenia.